Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast

Histopathology

Volumn 42, Issue 5, 2003, Pages 440-447

  Baqai, T ^a   Shousha, S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Androgen receptors; Breast; Breast carcinoma; c erbB 2; Ductal carcinoma in situ; Lobular carcinoma in situ; Oestrogen receptors; p53; Progesterone receptors

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; ONCOGENE C ERB; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038531075     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01612.x     Document Type: Article

References (36)

1. Harris EER, Solin LJ. The diagnosis and treatment of ductal carcinoma in situ of the breast. Breast J. 2000: 6; 78-95.
2. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996: 275; 913-918.
3. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992: 69; 1174-1181.
4. Chaudhuri B, Crist KA, Mucci S, Malafa M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993: 113; 134-137.
5. Poller DN, Snead DRJ, Roberts EC et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br. J. Cancer 1993: 68; 156-161.
6. Wilbur DC, Barrows GH. Estrogen and progesterone receptors and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod. Pathol. 1993: 6; 114-120.
7. National Coordinating Group for Breast Screening Pathology. Pathology reporting in breast cancer screening, 2nd edn. Sheffield: NHSBSP Publications, 1995.
8. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998: 51; 227-238.
9. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999: 353; 1993-2000.
10. Fisher ER, Dignam J, Tan-Chiu E et al. Pathologic findings from the National Surgical Adjuvant Breast Proiect (NSABP) eight-year update of protocol B-17. Intraductal carcinoma. Cancer 1999: 86; 429-438.
11. Silverstein MJ, Lagios MD, Groshen S et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N. Engl. J. Med. 1999: 340; 1455-1461.
12. Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast. Pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am. J. Surg. Pathol. 2000: 24; 1058-1067.
13. Ottesen GL, Graverson HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res. Treat. 2000: 62; 197-210.
14. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI, the Consensus Conference Committee, Consensus conference on the treatment of in situ ductal carcinoma of the breast April 22-25 1999. Cancer 2000: 88; 946-954.
15. Holland PA, Knox WF, Potten CS et al. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 1997: 89; 1059-1065.
16. Wilcken NRC. Tamoxifen hits the target in situ. Lancet 1999: 353; 1986-1987.
17. Quinn CM, Ostrowski JL. Cytological and architectural heterogeneity in ductal carcinoma of the breast. J. Clin. Pathol. 1997: 50; 596-599.
18. Consensus Conference on the Classification of Ductal Carcinoma in situ. Hum. Pathol. 1997: 28; 1221-1225.
19. Douglas-Jones AG, Morgan JM, Appleton MAC et al. Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast. J. Clin. Pathol. 2000: 53; 596-602.
20. Wells WA, Carney PA, Eliassen MS, Grove MR, Tosteson ANA. Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. Am. J. Surg. Pathol. 2000: 24; 651-659.
21. Sneige N, Lagios MD, Schwarting R et al. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum. Pathol. 1999: 30; 257-262.
22. Sannino P, Shousha S. Demonstration of oestrogen receptors in paraffin wax sections of breast carcinoma using the monoclonal antibody 1D5 and microwave oven processing. J. Clin. Pathol. 1994: 47; 90-92.
23. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J. Clin. Pathol. 2000: 53; 688-696.
24. Zafrani B, Aubriot M-H, Mouret E et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinomas: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000: 37; 536-545.
25. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erbB-2 protein. Cancer 1995: 75; 2123-2131.
26. Moreno A, Figueras A, Lloveras B et al. Apoptosis in ductal carcinoma in situ of the breast. Breast J. 2001: 7; 245-248.
27. Ottesen GL, Christensen IJ, Larsen JK et al. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res. Treat, 2000: 62; 219-226.
28. Roger P, Daures J-P, Maudelonde T et al. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum. Pathol. 2000; 31; 593-600.
29. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer 2001: 85; 869-874.
30. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU. Immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am. J. Clin. Pathol. 1992: 97 (Suppl.); S48-S52.
31. Borbow L, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J. Pathol. 1995: 176; 333-341.
32. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch. Pathol. Lab. Med. 1996: 120; 81-85.
33. Ho GH, Calvano JE, Bisogna M et al. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 2000: 89; 2153-2160.
34. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998: 82; 2382-2390.
35. Prasad ML, Osborne MP, Giri DD, Hoda SA. Microinvasive carcinoma (T1mic) of the breast. Clinicopathologic profile of 21 cases. Am. J. Surg. Pathol. 2000: 24; 422-428.
36. Scawn R, Shousha S. Morphological spectrum of estrogen receptor negative breast carcinoma. Arch. Pathol. Lab. Med. 2002: 126; 325-330.